Cargando…

Why “American Patients First” is likely to raise drug prices outside of the United States

Background: The Trump administration’s ‘American Patients First’ blueprint proposes to reduce drug prices in the USA by increasing drug prices abroad, ex USA. The possibility of the Trump administration to raise drug prices ex USA through legal action via the WTO and bilateral negotiations with fore...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dabbous, Monique, Milea, Cyprien, Simoens, Steven, François, Clement, Dussart, Claude, Chachoua, Lylia, Borissov, Borislav, Toumi, Mondher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Routledge 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713089/ https://www.ncbi.nlm.nih.gov/pubmed/31489151 http://dx.doi.org/10.1080/20016689.2019.1650596

Ejemplares similares

President Trump’s prescription to reduce drug prices: from the campaign trail to American Patients First
por: Dabbous, Monique, et al.
Publicado: (2019)

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
por: Chachoua, Lylia, et al.
Publicado: (2020)

Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies
por: Dabbous, Omar, et al.
Publicado: (2022)

Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
por: Jarosławski, Szymon, et al.
Publicado: (2018)

Patient-reported outcome claims in European and United States orphan drug approvals
por: Jarosławski, Szymon, et al.
Publicado: (2018)

Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers
por: Qiu, Tingting, et al.
Publicado: (2021)

Gene therapy randomised clinical trials in Europe – a review paper of methodology and design
por: Ilieva, Krassimira, et al.
Publicado: (2020)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
por: Badora, Karolina, et al.
Publicado: (2017)

Chinese guidelines related to novel coronavirus pneumonia
por: Qiu, Tingting, et al.
Publicado: (2020)

The impact of amortization of gene therapies funding on the results and conclusions of CEMs and BIMs
por: Polek, Hubert, et al.
Publicado: (2023)

A comparative study of orphan drug prices in Europe
por: Young, Katherine Eve, et al.
Publicado: (2017)

Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
por: Dahmani, Hajer, et al.
Publicado: (2023)

Systematic literature review on the implicit factors influencing the HTA deliberative process in Europe
por: Monleón, Clara, et al.
Publicado: (2022)

North American carbon black prices raised by $40–70 per tonne
Publicado: (2020)

Overview of external reference pricing systems in Europe
por: Rémuzat, Cécile, et al.
Publicado: (2015)

Determinants of orphan drugs prices in France: a regression analysis
por: Korchagina, Daria, et al.
Publicado: (2017)

Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Health economic evaluation of gene replacement therapies: methodological issues and recommendations
por: Aballéa, Samuel, et al.
Publicado: (2020)

Drug pricing reform in China: analysis of piloted approaches and potential impact of the reform
por: Chen, Yixi, et al.
Publicado: (2016)

From investigational product to active reference: evolution of oral sumatriptan efficacy versus placebo for the treatment of acute migraine episodes and potential impact in comparative analyses
por: Thokagevistk, Katia, et al.
Publicado: (2019)

Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update
por: Han, Ru, et al.
Publicado: (2019)

Outside the “Cultural Binary”: Understanding Why Latin American Collectivist Societies Foster Independent Selves
por: Krys, Kuba, et al.
Publicado: (2022)

Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe
por: Medic, Goran, et al.
Publicado: (2017)

New pricing models for generic medicines to ensure long-term sustainable competition in Europe
por: Francois, Clement, et al.
Publicado: (2023)

Resignations at Canada’s drug pricing panel raise independence questions
por: Vogel, Lauren
Publicado: (2023)

Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
por: Zhou, Junwen, et al.
Publicado: (2019)

Clinical management and associated costs for moderate and severe Alzheimer’s disease in urban China: a Delphi panel study
por: Yu, Xin, et al.
Publicado: (2015)

Evaluation of Prices for Surgical Procedures Within and Outside Hospital Networks in the US
por: Mullens, Cody Lendon, et al.
Publicado: (2023)

EE179 Key Drivers of the Economically Justifiable Price of the COVID-19 Vaccine in England
por: Aballea, S, et al.
Publicado: (2022)

Generic Medicine Pricing Policies in Europe: Current Status and Impact
por: Dylst, Pieter, et al.
Publicado: (2010)

Price Attractiveness and Price Complexity: Why People Prefer Level-Payment Loans
por: Lu, Yang, et al.
Publicado: (2021)

Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach
por: Han, Ru, et al.
Publicado: (2021)

Why Are Product Prices in Online Markets Not Converging?
por: Mizuno, Takayuki, et al.
Publicado: (2013)

The Market Access Society launches a new journal
por: Toumi, Mondher
Publicado: (2013)

Why Questionnaire Scores Are Not Measures: A Question-Raising Article
por: Tesio, Luigi, et al.
Publicado: (2023)

Why we should raise stroke awareness in the younger population?
por: Zhao, Jing, et al.
Publicado: (2023)

TiO(2) suppliers face disappointing demand & find it hard to raise prices
Publicado: (2003)

U.S. Federal Reserve Policies can cause Political instability by raising bread prices(*)
por: Koren, Ore, et al.
Publicado: (2022)

Shining a light in the black box of orphan drug pricing
por: Picavet, Eline, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kdc549n8krtnv7hkb8b0e2fv38